ECQ0.F Neurizon Therapeutics Limited
- Market cap
- EUR 25.2M
- P/E
- -
- P/B
- 3.27x
- ROE
- -84.3%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Jun 2026.
Is ECQ0.F undervalued?
Graham numberThe Graham number of Neurizon Therapeutics Limited cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Neurizon Therapeutics Limited fundamental analysis
No fundamental analysis for Neurizon Therapeutics Limited yet.
Neurizon Therapeutics Limited stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Neurizon Therapeutics Limited
Neurizon Therapeutics Limited, a clinical stage biotechnology company, engages in the development of treatments for neurodegenerative diseases in Australia. Its lead candidate is NUZ-001, a small molecule drug designed to support cellular protein homeostasis which is evaluated in Regimen I of the Phase 2/3 HEALEY ALS platform trial for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company was formerly known as PharmAust Limited and changed its…
Full company profileNeurizon Therapeutics Limited financial statements
Neurizon Therapeutics Limited annual financial statements (AUD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 3.38M | 2.82M | - | - | - |
| Gross Profit | 3.07M | 2.04M | - | - | - |
| Operating Income | -2.75M | -3.70M | -6.66M | -18.5M | -27.8M |
| EBITDA | - | -5.80M | -6.66M | -18.5M | -9.98M |
| Net Income | -1.71M | -6.21M | -7.67M | -16.6M | -10.7M |
| EPS | -0.01 | -0.02 | -0.02 | -0.03 | -0.01 |
| Balance Sheet | |||||
| Total Assets | 10.1M | 6.13M | 11.1M | 4.36M | 23.7M |
| Total Liabilities | 2.23M | 2.24M | 897K | 1.54M | 11.0M |
| Shareholders' Equity | 7.84M | 3.89M | 10.2M | 2.82M | 12.7M |
| Cash & Short-term Investments | 2.42M | 2.71M | 9.71M | 4.16M | 12.7M |
| Cash Flow | |||||
| Capital Expenditure | 43.4K | 34.9K | 0.00 | 1.55K | 8.22K |
| Free Cash Flow | -1.38M | -1.60M | -5.17M | -14.3M | -15.1M |
| Ratios | |||||
| ROE | -21.8% | -159.7% | -75.0% | -588.3% | -84.3% |
| ROA | -16.9% | -101.3% | -69.0% | -380.7% | -45.3% |
| Net Profit Margin | -50.5% | -220.0% | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Neurizon Therapeutics Limited dividends
Neurizon Therapeutics Limited has not paid dividends in the last 5 fiscal years.
Last stock split: 1:20 on Oct 30, 2015.
Who owns Neurizon Therapeutics Limited
- Insiders 29.33%
- Institutions 0.00%
- Public & others 70.67%
- Shares outstanding 855M
- Free float 513M
Neurizon Therapeutics Limited company profile
- Company name
- Neurizon Therapeutics Limited
- Ticker
- ECQ0.F
- ISIN
- AU0000357261
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- June
- Address
- 385 Bourke Street, Melbourne, VIC, Australia, 3000
- Phone
- 61 3 9692 7222
- Website
- neurizon.com
About Neurizon Therapeutics Limited
Neurizon Therapeutics Limited, a clinical stage biotechnology company, engages in the development of treatments for neurodegenerative diseases in Australia. Its lead candidate is NUZ-001, a small molecule drug designed to support cellular protein homeostasis which is evaluated in Regimen I of the Phase 2/3 HEALEY ALS platform trial for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company was formerly known as PharmAust Limited and changed its name to Neurizon Therapeutics Limited in October 2024. Neurizon Therapeutics Limited was incorporated in 2000 and is based in Melbourne, Australia.
Neurizon Therapeutics Limited management
10- Mr. Dan O'ConnellChief Financial Officer
- Dr. Chris-Carol Bremer M.B.A., M.D., Ph.D.Chief Executive Officer
- Mr. John ClarkChief Operating Officer
- Dr. Gary PittHead of Chemistry
- Dr. James RixsonHead of Production
- Dr. Herbert BrinkmanHead of Manufacturing
- Ms. Lidija DamjanovicHead of Market Engagement & Corporate Affairs
- Dr. Chris Freitag M.D.Chief Medical Advisor · born 1966
- Dr. Martin EngelHead of Scientific & Commercial Partnerships
- Ms. Linda McBride R.Ph. RACHead of Regulatory